Biotia Company Profile

Background

Biotia is a health-tech company based in New York, NY, specializing in combating infectious diseases through the integration of genomics and artificial intelligence (AI). Founded in 2016 as a spinout from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia's mission is to deploy the world's leading reference library of microbes to fight infectious diseases. The company operates a New York State CLIA-certified laboratory for infectious disease diagnostics, affiliated with SUNY Downstate Health Sciences University.

Key Strategic Focus

Biotia's strategic focus centers on:

Advanced Diagnostic Solutions: Developing sequencing-based assays and AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance.

Global Pathogen Surveillance: Implementing platforms like GeoSeeq to detect, predict, mitigate, and contain outbreaks globally, particularly in underserved regions.

Clinical and Research Applications: Offering products such as BIOTIA-ID for clinicians and BIOTIA-DX for researchers, enhancing diagnostic accuracy and research capabilities.

Financials and Funding

Biotia has successfully secured funding to support its growth and innovation:

Seed Round (December 2019): Raised $2.4 million, led by Falcon III Ventures, to advance diagnostic testing methods and AI-based software development.

Series A Round (August 2022): Raised an oversubscribed $8 million, led by OCA Ventures, with participation from Continuum Health Ventures, Phoenix Venture Partners, SeedtoB Capital, SK Square Americas, Digital-Dx Ventures, and others. The funds are intended to expand technical capabilities, compliance, and market reach.

Pipeline Development

Biotia's product pipeline includes:

BIOTIA-ID Urine: A genomics-based assay for urinary tract infections (UTIs), achieving 97% sensitivity and 99% specificity. In November 2024, it received New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) approval as a Laboratory Developed Test (LDT).

GeoSeeq: A global pandemic early warning system that integrates climate and health data to drive diagnostics, vaccines, and therapeutics.

BIOTIA-DX: A metagenomics tool for researchers, offering sensitivity surpassing traditional culture or qPCR methods.

Technological Platform and Innovation

Biotia's technological innovations include:

Chelsea™ Software: An AI-based platform capable of identifying over 16,000 microbial species, including antimicrobial resistance and virulence genetic markers, providing comprehensive microbial profiles and predicted drug resistance.

Sequencing-Based Assays: Utilizing next-generation DNA sequencing (NGS) to detect pathogens and antimicrobial resistance with high accuracy.

Leadership Team

Biotia's leadership comprises experts in genomics, AI, and healthcare:

Dr. Niamh O’Hara: Co-Founder & Chief Executive Officer.

Dr. Christopher Mason: Co-Founder & Global Director.

Dr. Dorottya Nagy-Szakal: Chief Medical Officer.

Dr. David Danko: Chief Technology Officer.

Janice Charley: Chief Financial Officer.

Lorenzo Uccellini, PhD: Director of Business Development.

Mara Couto-Rodriguez, MS: Director of Research and Development.

Caitlin Otto, PhD: Clinical Laboratory Director.

Teresa Rozza: Clinical Laboratory Supervising Technologist.

Zaineb Bello, MS: Clinical Laboratory Consultant.

Sol Rey: NGS Research Scientist.

Tiara Rivera: NGS Clinical Laboratory Technician.

Heather Wells, PhD: Senior Bioinformatician.

Ford Combs, PhD: Senior Bioinformatics Engineer.

Gábor Fidler, PhD: Bioinformatics Engineer.

John Papciak: Junior Bioinformatic Developer.

Ádám Nagyházy-Horváth: Director of Product.

Cory Mason: Information Technology Consultant.

Csaba Gura: DevOps Engineer.

Eszter Szöllősi: Software Engineer.

Tamás Nemcsok: Software Engineer.

Edit Szűcsné Balogh: Junior Software Engineer.

Leadership Changes

In December 2019, Biotia expanded its scientific and clinical advisory board to include Barry T. Zeman, Dr. Don Goldmann, and Dr. Steven Salzberg, enhancing the company's expertise in healthcare management, pediatrics, and biomedical engineering.

Competitor Profile

Market Insights and Dynamics

The infectious disease diagnostics market is experiencing significant growth, driven by the increasing prevalence of infectious diseases, advancements in diagnostic technologies, and the need for rapid and accurate pathogen identification. The integration of genomics and AI is transforming the landscape, offering more precise and comprehensive diagnostic solutions.